[go: up one dir, main page]

CL2018001192A1 - Análogos de saponina triterpeno - Google Patents

Análogos de saponina triterpeno

Info

Publication number
CL2018001192A1
CL2018001192A1 CL2018001192A CL2018001192A CL2018001192A1 CL 2018001192 A1 CL2018001192 A1 CL 2018001192A1 CL 2018001192 A CL2018001192 A CL 2018001192A CL 2018001192 A CL2018001192 A CL 2018001192A CL 2018001192 A1 CL2018001192 A1 CL 2018001192A1
Authority
CL
Chile
Prior art keywords
analogues
triterpene
saponin
compounds
saponin triterpene
Prior art date
Application number
CL2018001192A
Other languages
English (en)
Inventor
David Y Gin
Eric Chea
Alberto Fernandez-Tejada
Jeffrey Gardner
Jason Lewis
Philip Livingston
J Tyler Martin
Lars Nordstroem
Naga Vara Kishore Pillarsetty
Govind Ragupathi
Derek Tan
Original Assignee
Adjuvance Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvance Tech Inc filed Critical Adjuvance Tech Inc
Publication of CL2018001192A1 publication Critical patent/CL2018001192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A ADYUVANTES DERIVADOS DE GLICÓSIDOS DE SAPONINA TRITERPENO, LAS SÍNTESIS DE LOS MISMOS, E LOS INTERMEDIARIOS DE ELLO. LA SOLICITUD TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN Y LOS MÉTODOS PARA USAR DICHOS COMPUESTOS O COMPOSICIONES EN EL TRATAMIENTO DE Y LA INMUNIZACIÓN PARA ENFERMEDADES INFECCIOSAS.
CL2018001192A 2015-11-06 2018-05-03 Análogos de saponina triterpeno CL2018001192A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252296P 2015-11-06 2015-11-06
US201562268837P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
CL2018001192A1 true CL2018001192A1 (es) 2018-11-23

Family

ID=58662549

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001192A CL2018001192A1 (es) 2015-11-06 2018-05-03 Análogos de saponina triterpeno

Country Status (12)

Country Link
US (5) US20180327436A1 (es)
EP (2) EP3370730A4 (es)
JP (3) JP6900385B2 (es)
KR (1) KR20180077180A (es)
CN (2) CN112812143A (es)
AU (1) AU2016349693B2 (es)
CA (1) CA3003483C (es)
CL (1) CL2018001192A1 (es)
IL (3) IL293848B2 (es)
SG (2) SG10202012205XA (es)
WO (1) WO2017079582A1 (es)
ZA (1) ZA201802891B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202106403QA (en) * 2014-05-30 2021-07-29 Memorial Sloan Kettering Cancer Center Minimal saponin analogues, synthesis and use thereof
CN112812143A (zh) 2015-11-06 2021-05-18 佐剂技术公司 三萜皂苷类似物
WO2018191598A1 (en) * 2017-04-13 2018-10-18 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3697802A4 (en) * 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
US20230128815A1 (en) * 2020-03-23 2023-04-27 Adjuvance Technologies, Inc. Adjuvant compounds, salt forms, and formulations
EP4153210A4 (en) 2020-05-19 2024-11-13 Othair Prothena Limited MULTIPLE EPITOPE VACCINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2023536995A (ja) 2020-08-07 2023-08-30 オター プロシーナ リミテッド アルツハイマー病を処置するためのマルチエピトープワクチン
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
EP4429674A4 (en) * 2021-11-08 2025-10-08 Adjuvance Tech Inc ADJUVANT COMPOUNDS AND FORMULATIONS
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines
CN117106004A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 三萜皂苷化合物及其制备方法及应用
WO2024218268A1 (en) 2023-04-20 2024-10-24 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin derivatives as adjuvants and photoaffinity probes
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) 1974-03-12 1978-11-01
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
DK0651789T4 (da) 1992-07-17 2009-07-27 Merck & Co Inc Fremgangsmåde til at forebygge zoster eller lindre varicella-forbundet post-herpetisk neuralgia
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69725747T2 (de) 1996-08-23 2004-07-29 Sequus Pharmaceuticals, Inc., Menlo Park Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
ES2321769T3 (es) 1996-10-15 2009-06-10 Transave, Inc. Liposomas de n-acil fosfatidiletanolamina para el transporte de medicamentos.
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6262029B1 (en) * 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
AU7085400A (en) 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA018201B1 (ru) 2007-05-24 2013-06-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
CL2008003808A1 (es) 2007-12-21 2011-03-11 Glaxosmithkline Biologicals Sa Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna.
JP5706815B2 (ja) 2008-04-08 2015-04-22 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ トリテルペンであるサポニン、その合成法および使用
HUE026586T2 (hu) 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
KR102374576B1 (ko) 2011-05-17 2022-03-15 솔리제닉스, 인크. 열안정성 백신 조성물 및 그의 제조방법
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
SG10202106403QA (en) * 2014-05-30 2021-07-29 Memorial Sloan Kettering Cancer Center Minimal saponin analogues, synthesis and use thereof
CA2970840A1 (en) 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen
CN112812143A (zh) 2015-11-06 2021-05-18 佐剂技术公司 三萜皂苷类似物
WO2017106836A1 (en) 2015-12-17 2017-06-22 Memorial Sloan-Kettering Cancer Center Triterpene saponin variants, methods of synthesis and use thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018191598A1 (en) 2017-04-13 2018-10-18 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
CA3061205A1 (en) 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3615039A4 (en) 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
EP3697802A4 (en) 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
WO2021091997A1 (en) 2019-11-05 2021-05-14 Adjuvance Technologies, Inc. Varicella zoster

Also Published As

Publication number Publication date
US20240327443A1 (en) 2024-10-03
EP4001290A1 (en) 2022-05-25
ZA201802891B (en) 2020-01-29
CN112812143A (zh) 2021-05-18
WO2017079582A1 (en) 2017-05-11
IL259145A (en) 2018-06-28
IL259145B (en) 2021-09-30
US20180327436A1 (en) 2018-11-15
SG11201803594TA (en) 2018-05-30
JP2021152043A (ja) 2021-09-30
AU2016349693A1 (en) 2018-05-17
AU2016349693B2 (en) 2022-08-11
US20230219991A1 (en) 2023-07-13
CA3003483C (en) 2022-09-13
US12037355B2 (en) 2024-07-16
JP6900385B2 (ja) 2021-07-07
KR20180077180A (ko) 2018-07-06
US20200239509A1 (en) 2020-07-30
IL286493B (en) 2022-07-01
IL293848B1 (en) 2024-10-01
CN108778289A (zh) 2018-11-09
JP2023012519A (ja) 2023-01-25
IL293848A (en) 2022-08-01
CA3003483A1 (en) 2017-05-11
US10906926B2 (en) 2021-02-02
JP2018537527A (ja) 2018-12-20
CN108778289B (zh) 2020-11-17
US20210002316A1 (en) 2021-01-07
EP3370730A1 (en) 2018-09-12
IL293848B2 (en) 2025-02-01
SG10202012205XA (en) 2021-01-28
EP3370730A4 (en) 2019-07-31
IL286493A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CL2018001192A1 (es) Análogos de saponina triterpeno
CL2019003064A1 (es) Análogos de triterperno saponina.
CL2020000879A1 (es) Análogos de saponina de triterpeno.
CL2019002876A1 (es) Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2020001226A1 (es) Proceso para preparar tapinarof.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
UY35980A (es) Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
MX2017001279A (es) Usos y composiciones de la flagelina.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t